← All tickers

Is NGEN Worth Buying in 2026?

NervGen Pharma Corp. Common stock

STOCK stocks Updated 2026-05-24

Here’s whether NervGen Pharma Corp. Common stock (NGEN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.63% over 10 days); RSI 22 — oversold; 3-month momentum negative (-49.9%); rising volume on a downtrend (distribution, 2.44x avg). Currently 67.0% off its 52-week high. Score: -4/7.

Ready to act on this? 📈 Trade on Webull

NGEN is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 22.3 has dropped into oversold territory, which has historically preceded short-term bounces. With ~4 months of trading history, the return since first available bar is -65.2%. The current 67.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 4 months ago → $3,484 today

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 50-day MA ($3.86)
✗Above 13-day MA ($3.59)
!RSI(7) neutral zone (30–70) — currently 14.7
✗Positive return (-49.9%)
!Within 10% of period high (−55.5%)
Period Range $2.08
$2.02 $4.67
RSI (7) 14.7
0 · OversoldOverbought · 100

Key Metrics

Price$2.08
Period Return-49.9%
Period High$4.67
Period Low$2.02
Drawdown−55.5%
MA-13$3.59
MA-50$3.86
RSI (7)14.7
Avg Volume (30d)590K
vs. SPYtrailed by 58.4%

Trade NGEN

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers